Pyrazolone FPR2 Agonists for Inflammation Resolution and Plaque Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory diseases and cardiovascular conditions such as atherosclerosis and heart failure lack effective therapies that modulate the formyl peptide 2 (FPR2) receptor to promote resolution of inflammation and tissue healing.
Innovation Solution
Development of novel pyrazolone compounds that act as FPR2 receptor agonists, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates, which can be used in pharmaceutical compositions to treat inflammatory diseases, heart diseases, and other disorders by enhancing anti-inflammatory and healing responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for chronic inflammatory diseases and cardiovascular conditions are used, then existing therapeutic options are available, but effective therapies that modulate the FPR2 receptor to promote resolution of inflammation and tissue healing are lacking
Solution Approach 1:
The invention segments the therapeutic approach by developing specific pyrazolone compounds that selectively target the FPR2 receptor, separating this specific mechanism from general anti-inflammatory treatments. This allows precise modulation of FPR2 to promote resolution of inflammation and tissue healing while maintaining other therapeutic options for different disease aspects
Solution Approach 2:
The pyrazolone compounds act as intermediary substances that mediate between the administered drug and the FPR2 receptor. These compounds specifically bind to and activate FPR2, serving as a bridge to trigger pro-resolution pathways including Gi coupling, Ca2+ mobilization, and β-arrestin recruitment, thereby enabling effective modulation of inflammation resolution without directly interfering with other therapeutic mechanisms
2Reliability
If FPR2 agonists are developed to promote resolution of inflammation, then anti-inflammatory and healing responses are enhanced, but the complexity of the compound structure increases
Solution Approach 1:
The invention applies parameter changes by systematically modifying the pyrazolone core structure with various substituents (R1-R6 groups including aryl, heteroaryl, alkyl, and heterocyclic moieties) to optimize FPR2 agonist activity. This allows tuning of the compound's pharmacological properties to enhance anti-inflammatory responses while managing structural complexity through focused modification of key positions on the core scaffold
Data Source
AI summary
The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.